
## Janneke S Hoogstad-Van Evert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2316851/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Umbilical cord blood CD34 <sup>+</sup> progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rg <sup>null</sup> mice. OncoImmunology, 2017, 6, e1320630.	4.6	50
2	TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. Oncolmmunology, 2020, 9, 1843247.	4.6	48
3	Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients. Oncotarget, 2018, 9, 34810-34820.	1.8	44
4	Harnessing natural killer cells for the treatment of ovarian cancer. Gynecologic Oncology, 2020, 157, 810-816.	1.4	43
5	Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice. Blood, 2018, 131, 202-214.	1.4	40
6	IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells. Cancer Immunology, Immunotherapy, 2021, 70, 1305-1321.	4.2	27
7	Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study). Medicine (United States), 2019, 98, e14290.	1.0	20
8	CD34 <sup>+</sup> progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rg <sup>null</sup> mice. OncoImmunology, 2021, 10, 1981049.	4.6	13
9	The Promises of Natural Killer Cell Therapy in Endometriosis. International Journal of Molecular Sciences, 2022, 23, 5539.	4.1	8